285 related articles for article (PubMed ID: 21143869)
1. Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention Study.
Stocker M; Hop WC; van Rossum AM
BMC Pediatr; 2010 Dec; 10():89. PubMed ID: 21143869
[TBL] [Abstract][Full Text] [Related]
2. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns).
Stocker M; van Herk W; El Helou S; Dutta S; Fontana MS; Schuerman FABA; van den Tooren-de Groot RK; Wieringa JW; Janota J; van der Meer-Kappelle LH; Moonen R; Sie SD; de Vries E; Donker AE; Zimmerman U; Schlapbach LJ; de Mol AC; Hoffman-Haringsma A; Roy M; Tomaske M; Kornelisse RF; van Gijsel J; Visser EG; Willemsen SP; van Rossum AMC;
Lancet; 2017 Aug; 390(10097):871-881. PubMed ID: 28711318
[TBL] [Abstract][Full Text] [Related]
3. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial.
Stocker M; Fontana M; El Helou S; Wegscheider K; Berger TM
Neonatology; 2010; 97(2):165-74. PubMed ID: 19776651
[TBL] [Abstract][Full Text] [Related]
4. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients--calculated sample size: 1816 patients.
Assink-de Jong E; de Lange DW; van Oers JA; Nijsten MW; Twisk JW; Beishuizen A
BMC Infect Dis; 2013 Apr; 13():178. PubMed ID: 23590389
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
de Jong E; van Oers JA; Beishuizen A; Vos P; Vermeijden WJ; Haas LE; Loef BG; Dormans T; van Melsen GC; Kluiters YC; Kemperman H; van den Elsen MJ; Schouten JA; Streefkerk JO; Krabbe HG; Kieft H; Kluge GH; van Dam VC; van Pelt J; Bormans L; Otten MB; Reidinga AC; Endeman H; Twisk JW; van de Garde EMW; de Smet AMGA; Kesecioglu J; Girbes AR; Nijsten MW; de Lange DW
Lancet Infect Dis; 2016 Jul; 16(7):819-827. PubMed ID: 26947523
[TBL] [Abstract][Full Text] [Related]
6. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial.
Hochreiter M; Köhler T; Schweiger AM; Keck FS; Bein B; von Spiegel T; Schroeder S
Crit Care; 2009; 13(3):R83. PubMed ID: 19493352
[TBL] [Abstract][Full Text] [Related]
7. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.
Prkno A; Wacker C; Brunkhorst FM; Schlattmann P
Crit Care; 2013 Dec; 17(6):R291. PubMed ID: 24330744
[TBL] [Abstract][Full Text] [Related]
8. The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients.
Jensen JU; Lundgren B; Hein L; Mohr T; Petersen PL; Andersen LH; Lauritsen AO; Hougaard S; Mantoni T; Bømler B; Thornberg KJ; Thormar K; Løken J; Steensen M; Carl P; Petersen JA; Tousi H; Søe-Jensen P; Bestle M; Hestad S; Andersen MH; Fjeldborg P; Larsen KM; Rossau C; Thomsen CB; Ostergaard C; Kjaer J; Grarup J; Lundgren JD
BMC Infect Dis; 2008 Jul; 8():91. PubMed ID: 18620598
[TBL] [Abstract][Full Text] [Related]
9. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.
Shehabi Y; Sterba M; Garrett PM; Rachakonda KS; Stephens D; Harrigan P; Walker A; Bailey MJ; Johnson B; Millis D; Ding G; Peake S; Wong H; Thomas J; Smith K; Forbes L; Hardie M; Micallef S; Fraser JF; ;
Am J Respir Crit Care Med; 2014 Nov; 190(10):1102-10. PubMed ID: 25295709
[TBL] [Abstract][Full Text] [Related]
10. Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates.
Geraerds AJLM; van Herk W; Stocker M; El Helou S; Dutta S; Fontana MS; Schuerman FABA; van den Tooren-de Groot RK; Wieringa J; Janota J; van der Meer-Kappelle LH; Moonen R; Sie SD; de Vries E; Donker AE; Zimmerman U; Schlapbach LJ; de Mol AC; Hoffman-Haringsma A; Roy M; Tomaske M; Kornelisse RF; van Gijsel J; Visser EG; van Rossum AMC; Polinder S
Crit Care; 2021 Oct; 25(1):367. PubMed ID: 34670582
[TBL] [Abstract][Full Text] [Related]
11. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials.
Kopterides P; Siempos II; Tsangaris I; Tsantes A; Armaganidis A
Crit Care Med; 2010 Nov; 38(11):2229-41. PubMed ID: 20729729
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?
Sridharan P; Chamberlain RS
Surg Infect (Larchmt); 2013 Dec; 14(6):489-511. PubMed ID: 24274059
[TBL] [Abstract][Full Text] [Related]
13. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.
Schuetz P; Müller B; Christ-Crain M; Stolz D; Tamm M; Bouadma L; Luyt CE; Wolff M; Chastre J; Tubach F; Kristoffersen KB; Burkhardt O; Welte T; Schroeder S; Nobre V; Wei L; Bhatnagar N; Bucher HC; Briel M
Evid Based Child Health; 2013 Jul; 8(4):1297-371. PubMed ID: 23877944
[TBL] [Abstract][Full Text] [Related]
14. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis?
Harrison M; Collins CD
Infect Control Hosp Epidemiol; 2015 Mar; 36(3):265-72. PubMed ID: 25695167
[TBL] [Abstract][Full Text] [Related]
15. [Procalcitonine--early marker of neonatal infection].
Vasilcan G; Avasiloaiei A; Moscalu M; Dimitriu AG; Stamatin M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1243-50. PubMed ID: 22276477
[TBL] [Abstract][Full Text] [Related]
16. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis.
Kocabaş E; Sarikçioğlu A; Aksaray N; Seydaoğlu G; Seyhun Y; Yaman A
Turk J Pediatr; 2007; 49(1):7-20. PubMed ID: 17479639
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.
Schroeder S; Hochreiter M; Koehler T; Schweiger AM; Bein B; Keck FS; von Spiegel T
Langenbecks Arch Surg; 2009 Mar; 394(2):221-6. PubMed ID: 19034493
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of C reactive protein and others immunologic markers in the diagnosis of neonatal sepsis].
Zuppa AA; Calabrese V; D'Andrea V; Fracchiolla A; Scorrano A; Orchi C; Romagnoli C
Minerva Pediatr; 2007 Jun; 59(3):267-74. PubMed ID: 17519872
[TBL] [Abstract][Full Text] [Related]
19. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.
Nobre V; Harbarth S; Graf JD; Rohner P; Pugin J
Am J Respir Crit Care Med; 2008 Mar; 177(5):498-505. PubMed ID: 18096708
[TBL] [Abstract][Full Text] [Related]
20. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype?
Schuetz P; Christ-Crain M; Müller B
Swiss Med Wkly; 2009 Jun; 139(23-24):318-26. PubMed ID: 19529989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
